An Open-Label, Multi-Centre Study of Lapatinib in Combination With Chemotherapy in Patients With ErbB2 Overexpressing Breast Cancer After Trastuzumab Failure in the Neoadjuvant or Adjuvant Setting.
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2012
At a glance
- Drugs Capecitabine; Docetaxel; Lapatinib; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2010 Additional trial identifier (22059) identified as reported by ClinicalTrials.gov.
- 01 Jun 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 01 Jun 2010 Planned end date changed from 1 Oct 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov record.